



US009744239B2

(12) **United States Patent**
Kenney et al.

(10) **Patent No.:** **US 9,744,239 B2**
(45) **Date of Patent:** ***Aug. 29, 2017**

- (54) **VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION**
- (71) Applicant: **Par Pharmaceutical, Inc.**, Spring Valley, NY (US)
- (72) Inventors: **Matthew Kenney**, New Haven, MI (US); **Vinayagam Kannan**, Rochester, MI (US)
- (73) Assignee: **PAR PHARMACEUTICAL, INC.**, Chestnut Ridge, NY (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **14/717,877**
- (22) Filed: **May 20, 2015**
- (65) **Prior Publication Data**
US 2016/0220676 A1 Aug. 4, 2016
- Related U.S. Application Data**
- (63) Continuation of application No. 14/610,499, filed on Jan. 30, 2015.
- (51) **Int. Cl.**
A61K 47/10 (2017.01)
A61K 38/11 (2006.01)
A61K 9/00 (2006.01)
A61K 45/06 (2006.01)
A61K 47/12 (2006.01)
- (52) **U.S. Cl.**
CPC **A61K 47/10** (2013.01); **A61K 9/0019** (2013.01); **A61K 38/11** (2013.01); **A61K 45/06** (2013.01); **A61K 47/12** (2013.01)
- (58) **Field of Classification Search**
CPC C07K 7/16; A61K 38/11
See application file for complete search history.
- (56) **References Cited**

U.S. PATENT DOCUMENTS

4,542,124 A 9/1985 Huffman et al.
4,604,378 A 8/1986 Callahan et al.
4,684,622 A 8/1987 Ali et al.
4,746,508 A 5/1988 Carey et al.
4,762,820 A 8/1988 Gavras
4,764,378 A 8/1988 Keith et al.
4,767,628 A 8/1988 Hutchinson
4,781,871 A 11/1988 West, III et al.
5,042,975 A 8/1991 Chien et al.
5,124,315 A 6/1992 Ceschel et al.
5,192,741 A 3/1993 Orsolini et al.
5,204,112 A 4/1993 Hope et al.
5,225,212 A 7/1993 Martin et al.
5,250,022 A 10/1993 Chien et al.
5,252,263 A 10/1993 Hope et al.
5,288,497 A 2/1994 Stanley et al.
5,288,498 A 2/1994 Stanley et al.
5,359,030 A 10/1994 Ekwuribe

5,424,068 A 6/1995 Filip
5,482,931 A 1/1996 Harris et al.
5,698,516 A 12/1997 Nilsson et al.
5,702,717 A 12/1997 Cha et al.
5,770,559 A 6/1998 Manning et al.
5,776,885 A 7/1998 Orsolini et al.
5,785,989 A 7/1998 Stanley et al.
5,811,399 A 9/1998 Khavinson et al.
5,889,110 A 3/1999 Hutchinson
5,902,790 A 5/1999 Green et al.
5,972,894 A 10/1999 Sinackevich et al.
5,981,474 A 11/1999 Manning et al.
5,989,857 A 11/1999 Mundschenk
6,004,573 A 12/1999 Rath et al.
6,034,175 A 3/2000 Hutchinson
6,086,918 A 7/2000 Stern et al.
6,117,949 A 9/2000 Rath et al.
6,143,722 A 11/2000 Melin et al.
6,174,547 B1 1/2001 Dong et al.
6,180,608 B1 1/2001 Geffer et al.
6,187,756 B1 2/2001 Lee et al.
6,201,072 B1 3/2001 Rath et al.
6,264,981 B1 7/2001 Zhang et al.
6,287,588 B1 9/2001 Shih et al.
6,589,549 B2 7/2003 Shih et al.
6,592,894 B1 7/2003 Zarif et al.
6,630,486 B1 10/2003 Royer
6,720,001 B2 4/2004 Chen et al.
6,740,333 B2 5/2004 Beckett et al.
6,811,689 B2 11/2004 Zhang et al.
6,814,870 B2 11/2004 Zhang et al.
6,821,249 B2 11/2004 Casscells, III et al.
6,841,617 B2 1/2005 Jeong et al.
6,949,509 B2 9/2005 Woodrow

(Continued)

OTHER PUBLICATIONS

FDA Label for VASOSTRICT™, published Apr. 2014.*
Scott "Making the Medicine" BioProcess International, Mar. 2006, supplement, p. 42-56.*
Meyer et al. "Effects of Conformation on the Chemical Stability of Pharmaceutically Relevant Polypeptides," Chapter 4 in Rational Design of Stable Protein Formulations, Ed. Carpenter and Manning, 2002, pp. 85-107.*
Label for Angiomax® (bivalirudin) for Injection, 2000.*
Label for Oxytocin for Injection, Dec. 2000.*
Product Information for Liraglutide Victoza®, May 15, 2013.*
Public Assessment Report of the Medicines Evaluation Board in the Netherlands, Gonapeptyl 0.1 mg/1 ml, solution for injection, Ferring B.V., the Netherlands, triptorelin acetate, Feb. 2, 2010.*
Cetrotide® Cetrotorelix acetate Consumer Medicine Information, Apr. 2011.*

(Continued)

Primary Examiner — Christina Bradley

(74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

19 Claims, 10 Drawing Sheets